Medicare should allow for limits on the discounts required for innovative drugs subject to price negotiation as it develops the rules around implementing the program, Novartis Chairman and CEO Vasant Narasimhan said in an interview with the Pink Sheet.
“Are there any protections that [the Centers for Medicare and Medicaid Services] would consider for novel technologies, novel drugs …...







